{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:04:20Z","timestamp":1788519860710,"version":"build-2803163510"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1213\/ane.0b013e3181606fad","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T01:52:07Z","timestamp":1236217927000},"page":"628-637","source":"Crossref","is-referenced-by-count":90,"title":["Intrathecal Ziconotide for Severe Chronic Pain: Safety and Tolerability Results of an Open-Label, Long-Term Trial"],"prefix":"10.1213","volume":"106","author":[{"given":"Mark S.","family":"Wallace","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Rauck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G.","family":"Charapata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeeva","family":"Dissanayake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-41-20210902","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1527-3458.2000.tb00134.x","article-title":"Analgesic properties of ziconotide, a selective blocker of N-type neuronal calcium channels.","volume":"6","author":"Wang","year":"2000","journal-title":"CNS Drug Rev"},{"key":"R2-41-20210902","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1021\/bi00382a004","article-title":"Neuronal calcium channel antagonists. Discrimination between calcium channel subtypes using omega-conotoxin from Conus magus venom.","volume":"26","author":"Olivera","year":"1987","journal-title":"Biochemistry"},{"key":"R3-41-20210902","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1126\/science.2165278","article-title":"Diversity of Conus neuropeptides.","volume":"249","author":"Olivera","year":"1990","journal-title":"Science"},{"key":"R4-41-20210902","first-page":"6","article-title":"Venom peptides as human pharmaceuticals.","volume":"4","author":"Miljanich","year":"1997","journal-title":"Sci Med"},{"key":"R5-41-20210902","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0304-3959(94)00094-U","article-title":"Effect of continuous intrathecal infusion of omega-conopeptides, N-type calcium-channel blockers, on behavior and antinociception in the formalin and hot-plate tests in rats.","volume":"60","author":"Malmberg","year":"1995","journal-title":"Pain"},{"key":"R6-41-20210902","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jpainsymman.2005.10.003","article-title":"A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain.","volume":"31","author":"Rauck","year":"2006","journal-title":"J Pain Symptom Manage"},{"key":"R7-41-20210902","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.291.1.63","article-title":"Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial.","volume":"291","author":"Staats","year":"2004","journal-title":"JAMA"},{"key":"R8-41-20210902","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1525-1403.2006.00055.x","article-title":"Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double-blind, placebo-controlled clinical trial.","volume":"9","author":"Wallace","year":"2006","journal-title":"Neuromodulation"},{"key":"R9-41-20210902","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/00223980.1945.9917223","article-title":"A standardized memory scale for clinical use.","volume":"19","author":"Wechsler","year":"1945","journal-title":"J Psychol"},{"key":"R10-41-20210902","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/1097-4679(198707)43:4<402::AID-JCLP2270430411>3.0.CO;2-E","article-title":"Relationships between parts A and B of the Trail Making Test.","volume":"43","author":"Corrigan","year":"1987","journal-title":"J Clin Psychol"},{"key":"R11-41-20210902","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2466\/pms.1958.8.3.271","article-title":"Validity of the Trail Making Test as an indicator of organic brain damage.","volume":"8","author":"Reitan","year":"1958","journal-title":"Percept Mot Skills"},{"key":"R12-41-20210902","article-title":"PRIALT [package insert].","year":"2007"},{"key":"R13-41-20210902","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00002018-200730020-00001","article-title":"Open-label extension studies: do they provide meaningful information on the safety of new drugs?","volume":"30","author":"Day","year":"2007","journal-title":"Drug Saf"}],"container-title":["Anesthesia &amp; Analgesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1213\/ane.0b013e3181606fad","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:18:15Z","timestamp":1786112295000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000539-200802000-00041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1213\/ane.0b013e3181606fad","relation":{},"ISSN":["0003-2999"],"issn-type":[{"value":"0003-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}